Johnson & Johnson Patent-Cliff Exposure & CMS Drug Spending Portfolio
Johnson & Johnson (New Brunswick, NJ): 57 reconciled FDA prescription therapies (9.1% 2025 to 2030 cliff risk), $25.58B 2024 CMS Part D & Medicaid spend, and 124 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | New Brunswick, NJ |
| Reconciled FDA Portfolio Therapies | 57 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 9.1% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $25.58B |
| 2024 Medicare Part D Spend | $18.44B |
| 2024 Medicaid Spend | $7.15B |
| California HCAI SB 17 Filings | 124 WAC filings (max 26.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.